Back to search results

Studying the Use of Pharmacogenomic Testing in Routine Care

This study, called "The 1200 Patients Project," is looking at how useful pharmacogenomic testing (DNA tests to see how your body processes medicines) is in everyday medical care. Researchers at the University of Chicago Medical Center are collecting DNA samples from patients like you. They will test these samples to see if certain gene differences might mean you have a higher risk of side effects or a better chance of benefiting from specific medications. The results will be shared with your doctor, and the study will track if this information helps guide your treatment. The goal is to see if incorporating these tests into routine care is practical over five years. The study is currently unclear on its recruitment status.

Study design
This is an observational study involving 1200 participants. It is not a drug trial, but rather looks at the feasibility of using genetic information in patient care.
What's involved
You would provide a DNA sample. The study will then track whether the genetic information is used in your routine healthcare.
Compensation
Not stated in the trial record.
Follow-up
The feasibility of incorporating pharmacogenomic testing will be measured at 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01280825

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

Recruiting
Not specifiedAges 18+Observational
University of Chicago
~1,200 participants
Updated 2026-03-04 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of incorporating pharmacogenomic testing into routine medical care
Measured over 5 years

Conditions

Patients Undergoing Routine Health Care
Heart Diseases
Inflammatory Bowel Diseases
Autoimmune Disease
Inflammatory Disease
Blood Coagulation Disorders
Hepatitis C
Non-Metastatic Neoplasm

Explore related trials

Autoimmune DiseaseCoagulation DisorderHeart DisorderHepatitis C InfectionInflammatory Bowel DiseaseInflammatory DisorderNeoplasm

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Peter H O'Donnell, MD · PRINCIPAL_INVESTIGATOR · University of Chicago

Who to contact

1200 Patients Project Study Team
[email protected]
(773) 834-1759
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Receiving ongoing, out-patient care at the University of Chicago Medical Center under the routine care of a physician participating in this trial
Life expectancy of at least 3 years
Must be 18 years or older
Must be taking at least 1 (but not more than 6) prescription medications at the time of enrollment OR be 65 years or older OR be reasonably expected to require the use of a prescription medication within the next 5 years
Patients with certain diseases, or likely to receive or be receiving certain drugs, will be targeted particularly for enrollment in order to enrich the study for patients likely to have pharmacogenetically relevant interactions, including, but not limited to:
Patients requiring specialized cardiology care
Patients with inflammatory bowel diseases
Patients with systemic autoimmune or inflammatory diseases
Patients requiring long-term oral anticoagulation
Patients with hepatitis C
Patients with non-metastatic cancer

Exclusion

Patients with acute or chronic disease which could be reasonably expected to result in the patient's death within the next 3 years.
Patients who have undergone, or are being actively considered for, liver or kidney transplantation.
Inability to understand and give informed consent to participate.

What this trial measures

  • Feasibility of incorporating pharmacogenomic testing into routine medical care5 years